Crossover study is a clinical trial in which the participants of the study get treatments randomly each. The patients in this study serves as control of their own individually. This kind of study is considered by researchers in situations difficult to get voluntary participants where there is no assurance of a new treatment (Dunn, Saunders, Rutter & Sullivan, 2010). The crossover study have interventions that impact the patient after the study for example; drug application experiment time matters where other patients in poorly controlled may die early because of the disease progression and thus such patients are not in a position to receive experimental drug after the study of crossover.
In such a scenario despite the crossover there is both the progression free survival (PFS) and overall survival (OS) benefit. The crossover trial in oncology gives the patient an opportunity to move over to treatment from the progression of the disease in a planned manner to cover-up the ethical issues (Dunn et. al, 2010). In such a case, it is justifiable the intervention has PFS advantage and not an OS because of the crossover. Cohort studies involve medicinal research to find out what causes diseases and to bring forth links that connect the risk factors and the health outcomes. The prospective studies are best when planned and administered in the future time. Studies that are usually prospective are usually planned in advance while they get carried out over a period of time in the future. Cohort studies that are retrospective look at already existing data and try figure risk factors that are particular in nature. However, interpretations are usually limited because researchers never get the opportunity to go back and get missing data. Diseases best to study include cardiovascular, arthritis and diabetes.
Delegate your assignment to our experts and they will do the rest.
References
Dunn, K. M., Saunders, K. W., Rutter, C. MSullivan, M. D.(2010). Opioid prescriptions for chronic pain and overdose: a cohort study. Annals of internal medicine, 152(2), 85-92.
